In an article published in the journal Cell, Marc Therrien’s team explains the recent discovery of a protein complex that controls the RAS/MAPK signalling pathway, responsible for some of the deadliest cancers, including pancreatic, colon and lung cancers, and melanomas. This regulating mechanism could prove to be a promising therapeutic target for the treatment of these diseases. The study conducted on the drosophila model organism is to be verified in humans in a forthcoming step. Marc Therrien and his team focus their research on the RAS/MAPK signalling pathway, which is deregulated in several tumours. To send a message to the cell, the information must be relayed by proteins contained in this signalling pathway. In the case of the RAS/MAPK pathway, the message is given by RAS and the last protein in the pathway, MAPK, transmits the message to the cell’s control centre, the nucleus. However, the RAS/MAPK pathway sometimes transmits erroneous messages which cause the cell to proliferate non-stop.
“Our study shows that a protein complex, EJC, controls production of the MAPK protein, which acts directly on the cell. When this complex is deficient, the signalling pathway is inhibited which restricts the chaotic proliferation of the cell at the origin of many cancers,” Marc Therrien explains. “If we target EJC and the factors that regulate its activity, we could potentially prevent the transmission of abnormal signals that trigger several cancers.”
In addition to serving as a promising therapeutic target for treating cancer, the regulating mechanism discovered for MAPK could also apply to several other genes. “Our research could serve to explain the production of other proteins with a behaviour similar to MAPK. This mechanism could help us to understand gene expression in general,” Marc Therrien concludes.
The breakthrough was made possible by the SOLiD™ Next Generation Sequencing System manufactured by Life Technologies, which enabled the researchers to view the overall consequences of the elimination of EJC on the expression of all of the cell’s genes. “IRIC has adopted a cutting-edge technological infrastructure, without which this kind of work would be impossible,” explains Dr. Guy Sauvageau, Chief Executive Officer and Scientific Director of the IRIC. “The Life Technologies sequencing equipment allows us to perform cutting-edge research by quickly obtaining accurate and complete results.”
About IRIC | Institute for Research in Immunology and Cancer
Founded in 2002, IRIC brings together a team of internationally recognized investigators whose mission is to unravel the mysteries of cancer and to provide unparalleled training to the next generation of health research scientists. IRIC engages in bold initiatives with elite partners across North America and abroad that span from basic science and translational research to clinical applications, with the ultimate goal of providing lifelong cures to cancer. For more information about IRIC, please visit www.iric.ca.
Ashton-Beaucage D, Udell CM, Lavoie H, Baril C, Lefrançois M, Chagnon P, Gendron P, Caron-Lizotte O, Bonneil E, Thibault P, Therrien M. (2010) The exon junction complex controls the splicing of MAPK and other long intron-containing transcripts in Drosophila. Cell 143 :251-262
Media Relations Officer
Institute for Research in Immunology and Cancer
Université de Montréal